Bioasis Technologies Inc.

OTCPK:BIOA.F Stock Report

Market Cap: US$288.8k

Bioasis Technologies Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Deborah Rathjen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.1yrs
CEO ownership0.2%
Management average tenureno data
Board average tenure5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Deborah Rathjen's remuneration changed compared to Bioasis Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Nov 30 2022n/an/a

-CA$3m

Aug 31 2022n/an/a

-CA$3m

May 31 2022n/an/a

-CA$3m

Feb 28 2022CA$307kCA$209k

-CA$3m

Nov 30 2021n/an/a

-CA$3m

Aug 31 2021n/an/a

-CA$1m

May 31 2021n/an/a

CA$1m

Feb 28 2021CA$268kCA$190k

CA$698k

Nov 30 2020n/an/a

CA$754k

Aug 31 2020n/an/a

-CA$494k

May 31 2020n/an/a

-CA$4m

Feb 29 2020CA$282kCA$192k

-CA$4m

Nov 30 2019n/an/a

-CA$4m

Aug 31 2019n/an/a

-CA$4m

May 31 2019n/an/a

-CA$3m

Feb 28 2019CA$105kn/a

-CA$3m

Nov 30 2018n/an/a

-CA$5m

Aug 31 2018n/an/a

-CA$6m

May 31 2018n/an/a

-CA$6m

Feb 28 2018CA$283kn/a

-CA$5m

Compensation vs Market: Insufficient data to establish whether Deborah's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Deborah's compensation has increased whilst the company is unprofitable.


CEO

Deborah Rathjen (65 yo)

5.1yrs

Tenure

CA$306,657

Compensation

Dr. Deborah Ann Rathjen, B.Sc. (Hons.), Ph D., M.A.I.C.D., FTSE, Q.C. has been the President and Chief Executive Officer of Bioasis Technologies Inc. since March 11, 2019. Dr. Rathjen served as the Chief E...


Board Members

NamePositionTenureCompensationOwnership
Deborah Rathjen
Executive Chairman6.6yrsCA$306.66k0.22%
CA$ 649.4
David Wurzer
Independent Lead Director5.8yrsCA$93.60k0.067%
CA$ 194.8
Jeffrey Cummings
Member of Scientific Advisory Board6.6yrsno datano data
John Wikswo
Member of Scientific Advisory Board6.6yrsno datano data
John Krystal
Chairman of Scientific Advisory Board6.6yrsno datano data
Mario Saltarelli
Independent Non-Executive Director4.9yrsCA$93.60kno data
Hope Rugo
Member of Medical Oncology Advisory Board4.3yrsno datano data
John Hoppin
Member of Scientific Advisory Board5.8yrsno datano data
John de Groot
Member of Medical Oncology Advisory Board4.3yrsno datano data
Sue O'Connor
Member of Scientific Advisory board5.8yrsno datano data
John Curran
Independent Director5.8yrsCA$93.60k0.067%
CA$ 194.6
Javier Cortés
Member of Medical Oncology Advisory Board4.3yrsno datano data

5.8yrs

Average Tenure

65yo

Average Age

Experienced Board: BIOA.F's board of directors are considered experienced (5.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.